Randomized double-blind, placebo-controlled multi-center trial for determining efficacy of molecular hydrogen water for Parkinson’s disease, Baseline characteristics

Parkinsonism & Related Disorders ◽

10.1016/j.parkreldis.2015.10.183 ◽

2016 ◽

Vol 22 ◽

pp. e88-e89

Author(s):

Asako Yoritaka ◽

Nobutaka Hattori

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Molecular Hydrogen ◽

Double Blind ◽

Double Blind Placebo ◽

Hydrogen Water ◽

Baseline Characteristics

Download Full-text

A randomized double-blind, placebo-controlled multi-center trial of molecular hydrogen water for Parkinson’s disease

Journal of the Neurological Sciences ◽

10.1016/j.jns.2017.08.2972 ◽

2017 ◽

Vol 381 ◽

pp. 1052

Author(s):

A. Yoritaka ◽

T. Abe ◽

C. Ohtsuka ◽

T. Maeda ◽

M. Hirayama ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Molecular Hydrogen ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

Movement Disorders ◽

10.1002/mds.22218 ◽

2008 ◽

Vol 23 (15) ◽

pp. 2194-2201 ◽

Author(s):

C. Warren Olanow ◽

Robert A. Hauser ◽

Joseph Jankovic ◽

William Langston ◽

Anthony Lang ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying Therapy ◽

Baseline Characteristics ◽

Disease Modifying

Download Full-text

Erratum to: A randomized double-blind multi-center trial of hydrogen water for Parkinson’s disease: protocol and baseline characteristics

BMC Neurology ◽

10.1186/s12883-017-0817-2 ◽

2017 ◽

Vol 17 (1) ◽

Author(s):

Asako Yoritaka ◽

Takashi Abe ◽

Chigumi Ohtsuka ◽

Tetsuya Maeda ◽

Masaaki Hirayama ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Double Blind ◽

Hydrogen Water ◽

Baseline Characteristics

Download Full-text

A randomized double-blind multi-center trial of hydrogen water for Parkinson’s disease: protocol and baseline characteristics

BMC Neurology ◽

10.1186/s12883-016-0589-0 ◽

2016 ◽

Vol 16 (1) ◽

Author(s):

Asako Yoritaka ◽

Takashi Abe ◽

Chigumi Ohtsuka ◽

Tetsuya Maeda ◽

Masaaki Hirayama ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Double Blind ◽

Hydrogen Water ◽

Baseline Characteristics

Download Full-text

Faculty Opinions recommendation of Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737065221.793569342 ◽

2020 ◽

Author(s):

Joseph Jankovic ◽

Arjun Tarakad

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8286956.8718054 ◽

2011 ◽

Author(s):

Irene Litvan ◽

Rita Simoes

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Depressive Symptoms ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8638956.9139058 ◽

2011 ◽

Author(s):

John O'Brien ◽

John-Paul Taylor

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Dementia With Lewy Bodies ◽

Controlled Trial ◽

Lewy Bodies ◽

Parkinson’S Disease Dementia ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Pingchan granule for depressive symptoms in parkinson’s disease: A randomized, double-blind, placebo-controlled trial

Journal of Integrative Medicine ◽

10.1016/j.joim.2020.12.006 ◽

2020 ◽

Author(s):

Si-chun Gu ◽

Jie Zhou ◽

Qing Ye ◽

Can-xing Yuan

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Depressive Symptoms ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

P1-067: AMBROXOL AS PHARMACOLOGICAL CHAPERONE TARGETING GBA1 AS A DISEASE MODIFYING TREATMENT FOR PARKINSON'S DISEASE DEMENTIA: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Alzheimer s & Dementia ◽

10.1016/j.jalz.2018.06.069 ◽

2006 ◽

Vol 14 (7S_Part_5) ◽

pp. P296-P296

Author(s):

Stephen H. Pasternak ◽

Carolina Silveira ◽

Zhonghan Li ◽

Robert Bartha ◽

Michael Borrie ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Controlled Trial ◽

Phase 2 ◽

Parkinson’S Disease Dementia ◽

Double Blind ◽

Pharmacological Chaperone ◽

Double Blind Placebo ◽

Disease Modifying ◽

Disease Modifying Treatment

Download Full-text

P2.098 Saflnamide as an adjunct to levodopa signiflcantly improved motor fluctuations in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study

Parkinsonism & Related Disorders ◽

10.1016/s1353-8020(09)70449-3 ◽

2009 ◽

Vol 15 ◽

pp. S115

Author(s):

R. Borgohain ◽

J. Szasz ◽

M. Bhatt ◽

S. Rossetti ◽

V. Lucini ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Motor Fluctuations ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text